Paul Nyirjesy, MD
Obstetrics & Gynecology · Philadelphia, PANPI 1982660643
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Organon at 37.0% of the total. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $650.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$6K
- Cepheid$4K
- Gen-probe, Inc.$3K
- Gen-probe Sales & Service, Inc.$900
- New American Therapeutics, Inc.$867
- AMAG Pharmaceuticals, Inc.$375
- plus $510 from 2 others
Across 3 payments — averaging $9213.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gen-probe, Inc.$26K
- Hologic Inc$1K
What the payments were for
- Consulting fees$5,60836%
- Speaking & faculty fees$7,74350%
- Travel & lodging$1,76811%
- Food & beverage$4893%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 9 | $5,769 |
| Cepheid | 3 | $4,020 |
| Gen-probe, Inc. | 5 | $3,167 |
| Gen-probe Sales & Service, Inc. | 1 | $900 |
| New American Therapeutics, Inc. | 3 | $867 |
| AMAG Pharmaceuticals, Inc. | 1 | $375 |
| BD | 1 | $300 |
| Scynexis, Inc. | 1 | $210 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,608 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 641 | $66,125 |
| PremarinEstrogens, Conjugated | 55 | $29,495 |
| YuvafemEstradiol | 59 | $13,717 |
| Clobetasol Propionate | 207 | $6,245 |
| OsphenaOspemifene | 11 | $2,604 |
| ValacyclovirValacyclovir Hcl | 16 | $1,840 |
| Clindamycin Phosphate | 22 | $1,386 |
| Halobetasol Propionate | 15 | $1,037 |
| Amitriptyline Hcl | 37 | $941 |
| Gabapentin | 24 | $860 |
| Fluconazole | 79 | $792 |
| Betamethasone Dipropionate | 20 | $777 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 16 | $761 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $448 |
| Nortriptyline Hcl | 12 | $300 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Philadelphia
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
- Jamille Nagtalon-RamosPhiladelphia$183K
- Matthew BesharaPhiladelphia$56K
- Karolynn EcholsPhiladelphia$38K
- Miriam RaffeldPhiladelphia$33K
- Dana ShanisPhiladelphia$33K
- Alex SorianoPhiladelphia$22K
- Dacarla AlbrightPhiladelphia$20K
- Rupsa BoeligPhiladelphia$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.